Dodson Joseph, Kelm Ryan, Cavanaugh Kevin
Rush University Medical Center, Chicago, IL, United States.
Rush University Medical Center, Department of Dermatology, Chicago, IL, United States.
JPRAS Open. 2022 Sep 9;34:168-172. doi: 10.1016/j.jpra.2022.09.001. eCollection 2022 Dec.
The management of advanced basal cell carcinoma (BCC) can be challenging and often involves a multi-disciplinary approach with dermatologists, plastic surgeons, and oncologists. Standard therapy for advanced BCCs has historically involved prompt excision and radiation; however, in recent years, management strategies utilizing hedgehog pathway inhibitors as neoadjuvant therapy have gained popularity. While controversy regarding management recommendations still exists, we present a case of advanced BCC with cranial involvement in an immunocompromised patient where the use of neoadjuvant vismodegib led to a favorable outcome and, surprisingly, complete the pathologic clearance of the tumor.
晚期基底细胞癌（BCC）的治疗具有挑战性，通常需要皮肤科医生、整形外科医生和肿瘤学家采取多学科方法。从历史上看，晚期BCC的标准治疗方法包括及时切除和放疗；然而，近年来，使用刺猬通路抑制剂作为新辅助治疗的管理策略越来越受欢迎。虽然关于管理建议的争议仍然存在，但我们报告了一例免疫功能低下患者的晚期BCC伴颅骨受累病例，其中使用新辅助维莫德吉取得了良好的效果，令人惊讶的是，肿瘤实现了病理完全清除。
